Discontinuing methotrexate to enhance vaccine response.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35869395.
- Also identified by DOI 10.1038/s41584-022-00817-0 and PMC identifier 9306233.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In patients with autoimmune rheumatic disease, methotrexate therapy has been associated with poor immune response to vaccines, including those intended to provide protection against COVID-19. Emerging evidence supports the practice of temporarily discontinuing this treatment in order to improve immunogenicity.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Vaccines